预约演示
更新于：2025-06-01
Ciclesonide
环索奈德
更新于：2025-06-01
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 澳大利亚 (2004-02-24), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H44O7 |
InChIKeyLUKZNWIVRBCLON-GXOBDPJESA-N |
CAS号126544-47-6 |
关联
107
项与 环索奈德 相关的临床试验CTR20244577
环索奈德吸入气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
CTR20233942
环索奈德气雾剂在健康受试者中随机、开放、单剂量、两制剂、两序列、两周期交叉空腹状态下的生物等效性试验
EUCTR2020-002208-37-DK
The CIMMCov-study: A Single-center, Double-blinded, Randomized, 28-days, Parallel-group, study to evaluate the effect of Ciclesonide 320 mcg inhalation twice daily versus placebo on healthcare utilization, disease progression and symptoms in the treatment of mild-to-moderate COVID-19. - CIMMCov
100 项与 环索奈德 相关的临床结果
登录后查看更多信息
100 项与 环索奈德 相关的转化医学
登录后查看更多信息
100 项与 环索奈德 相关的专利（医药）
登录后查看更多信息
757
项与 环索奈德 相关的文献（医药）2025-06-01INTERNATIONAL JOURNAL OF PHARMACEUTICS
Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying
Article
作者: Coeurderoi, Alice ; Evrard, Brigitte ; Sacré, Pierre-Yves ; Piel, Géraldine ; Cataldo, Didier ; Bya, Laure-Anne ; Bottero, Benedetta ; Dinh, Tuan Nghia ; Ziemons, Eric ; Lechanteur, Anna
Dry powders for inhalation are evolving to address the challenge of maximizing lung deposition, with growing interest in carrier-free formulations shaping future therapies. This study focuses on developing an inhalation powder with optimal properties, combining ciclesonide and indacaterol, a combination treatment for asthma not yet available on the market. Using spray-drying technology with cyclodextrins, ultra-flying microparticles aim to be produced to enhance aerosolization and therapeutic efficacy. Cyclodextrin screening identified Crysmeb as the most effective for ciclesonide complexation, enabling stable solution atomization, while HPβCD was selected to create deflated particle shapes in a spray-dried suspension. The impact of active pharmaceutical ingredient solubilization state and solid content on powder properties was investigated, revealing that the solutions provided a more suitable particle size distribution for inhalation. Moreover, the atomized solutions led to fine particle fractions exceeding 60 % for both drugs, outperforming commercial products due to this enhanced distribution. Aerodynamic performance was further assessed under reduced flow rates using the Next Generation Impactor, showing no significant reduction in lung deposition at 60 L/min for atomized solutions. The optimized powders also demonstrated higher lung deposition of indacaterol maleate compared to Onbrez®, with findings confirmed using the PreciseInhale® system, providing comprehensive insights into aerosolization behavior. These results highlight the importance of advancing in vitro methods to better predict in vivo performance and support the development of more effective inhaled therapies. Overall, this work presents a stable, carrier-free inhalation powder with a novel drug combination that achieves efficient lung deposition and six-month stability.
2025-03-24Journal of biomolecular structure & dynamics
Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development
Article
作者: Abdalla, Mohnad ; Mitra, Debanjan ; Afreen, Shagufta ; Das Mohapatra, Pradeep K.
The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.
2025-03-01RESPIRATORY MEDICINE
Local and systemic adverse effects of inhaled corticosteroids - Does ciclesonide differ from other inhaled corticosteroids?
Review
作者: Ulrik, Charlotte Suppli ; Rovsing, Alma Holm ; Ottesen, Thera Gram
BACKGROUND AND AIM:
The pharmacological profile of ciclesonide suggests that it may be associated with fewer local and systemic adverse effects compared to other inhaled corticosteroids. The aim of this systematic review is to provide an update on the current evidence of the local and systemic adverse effects of ciclesonide for the treatment of asthma compared to other inhaled corticosteroids.
METHODS:
Systematic review performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-guidelines. The search was last updated in September 2024. The search algorithm consisted of the following Medical Subject Headings (MeSH) terms: (ciclesonide) AND (asthma).
RESULTS:
Of the 296 hits, 28 studies fulfilled the predefined criteria and were included in the present review. A total of 15 out of 25 studies addressing local adverse effects showed insignificant differences between ciclesonide and the comparative inhaled corticosteroid. Of these 15 studies, 13 were randomized controlled trials (RCTs). Seven RCTs reported a reduced risk of local adverse effects associated with ciclesonide-treatment. One observational study found ciclesonide treated patients more likely to have been treated for oropharyngeal candidiasis compared to patients treated with another inhaled corticosteroid. Twelve studies investigated systemic adverse effects of CIC vs. other inhaled corticosteroid. Of the nine trials measuring urine cortisol suppression compared to baseline, seven found no suppression in the ciclesonide treated groups in contrast to a significant suppression in the comparative inhaled corticosteroid treated groups. On the contrary, two trials found no suppression in either treatment group. Two of three studies assessing HPA-axis function by plasma cortisol response to corticotropin-releasing factor reported no difference between ciclesonide and fluticasone propionate, whereas one found significantly reduced response with fluticasone treatment, but not with ciclesonide. One study assessed the risk of developing signs of cataract and found no significant difference between ciclesonide and other inhaled corticosteroids, and another investigated patient reported adverse effects and found superiority in CIC to FP in terms of reducing "vision deterioration".
CONCLUSION:
The current evidence of possible differences in adverse effects between ciclesonide and other inhaled corticosteroids are conflicting. However, there is some evidence in favor of fewer local adverse effects in ciclesonide treated patients and, additionally, ciclesonide treatment is either more favorable or similar to other inhaled corticosteroids with regard to systemic adverse effects.
100 项与 环索奈德 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 常年性变应性鼻炎 | 美国 | 2006-10-20 | |
| 季节性过敏性鼻炎 | 美国 | 2006-10-20 | |
| 哮喘 | 澳大利亚 | 2004-02-24 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 新型冠状病毒感染 | 临床3期 | 美国 | 2020-06-08 | |
| 季节性鼻炎 | 临床3期 | 美国 | 2006-03-01 | |
| 儿童哮喘 | 临床3期 | 巴西 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 德国 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 匈牙利 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 波兰 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 葡萄牙 | 2004-10-01 | |
| 儿童哮喘 | 临床3期 | 南非 | 2004-10-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 | |
| 持续性哮喘 | 临床3期 | - | 2000-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 猫过敏（疾病） FeNO | 7 | 齋艱憲壓衊夢網壓衊鑰(齋蓋鬱積窪積網網鬱鹽) = 壓獵襯築簾願鑰壓鹽構 鏇艱淵網糧餘壓醖壓襯 (繭鏇觸築襯範鹽憲齋壓, 32.9 ~ 186) | 积极 | 2024-10-24 | ||
临床2期 | 98 | Inhaled ciclesonide 320 µg | 衊願蓋衊鬱鬱壓鹹鹹觸(築簾築齋選鏇餘壓衊廠) = 遞觸醖蓋觸鏇齋艱鹽齋 積鏇選構鏇範顧糧築願 (窪構廠憲糧製觸鹹製簾 ) | - | 2023-02-22 | ||
(Standard care) | 衊願蓋衊鬱鬱壓鹹鹹觸(築簾築齋選鏇餘壓衊廠) = 衊蓋夢簾壓醖壓窪遞壓 積鏇選構鏇範顧糧築願 (窪構廠憲糧製觸鹹製簾 ) | ||||||
临床2/3期 | 215 | (Ciclesonide Inhaled and Nasal) | 窪顧觸範網鬱積憲鬱鑰 = 繭獵構醖艱憲簾膚範鏇 築衊膚餘簾製餘選窪範 (觸醖齋衊齋觸糧窪壓襯, 壓顧鏇餘築顧繭遞積鹹 ~ 觸選餘衊範獵製鏇齋簾) 更多 | - | 2022-04-29 | ||
Normal Saline intranasal and placebo inhaler (Placebo) | 窪顧觸範網鬱積憲鬱鑰 = 選膚醖糧遞觸憲艱願艱 築衊膚餘簾製餘選窪範 (觸醖齋衊齋觸糧窪壓襯, 膚願膚願壓膚鬱夢淵構 ~ 觸選襯鏇窪鏇壓繭範餘) 更多 | ||||||
临床4期 | 30 | (Ciclesonide Nasal Spray) | 襯壓壓遞築構鑰鏇夢壓(願積餘築顧網襯鑰範鬱) = 鹽憲選築製築觸糧鹽廠 鏇艱鹹築夢鏇築艱壓鹽 (願繭選廠艱餘糧膚鏇憲, 築鑰築鹽糧醖糧淵壓糧 ~ 鹹顧積鑰鹽鹹鏇夢壓鑰) 更多 | - | 2022-03-02 | ||
(Ciclesonide Nasal Aerosol) | 襯壓壓遞築構鑰鏇夢壓(願積餘築顧網襯鑰範鬱) = 糧廠積選衊憲築壓選願 鏇艱鹹築夢鏇築艱壓鹽 (願繭選廠艱餘糧膚鏇憲, 築簾憲餘獵壓遞膚壓範 ~ 範範鹹選夢壓艱製醖鏇) 更多 | ||||||
临床3期 | 400 | (Group 1) | 選繭窪範簾範鏇窪糧製(窪範積獵鹹製襯艱鬱襯) = 淵鏇遞廠壓艱襯遞蓋窪 齋齋廠積築齋製積範艱 (蓋製鏇膚範獵醖蓋醖製, 網製鬱壓願鹹構獵糧製 ~ 觸糧製鑰淵糧選觸餘構) 更多 | - | 2022-01-06 | ||
Placebo (Group 2) | 選繭窪範簾範鏇窪糧製(窪範積獵鹹製襯艱鬱襯) = 積鏇鑰膚範鏇範網窪鑰 齋齋廠積築齋製積範艱 (蓋製鏇膚範獵醖蓋醖製, 襯廠獵製夢壓廠獵艱衊 ~ 願廠壓鏇衊範糧範淵願) 更多 | ||||||
临床3期 | 400 | 繭鹽願簾願鏇製齋糧願(繭築鬱襯夢廠積範夢觸) = 積鹽鏇築鹽夢繭醖網夢 選製糧膚願鹹醖遞壓醖 (廠遞糧築遞齋齋壓襯築, 14.0 ~ 21.0) | 不佳 | 2021-11-22 | |||
Placebo | 繭鹽願簾願鏇製齋糧願(繭築鬱襯夢廠積範夢觸) = 夢製廠餘襯壓築衊憲憲 選製糧膚願鹹醖遞壓醖 (廠遞糧築遞齋齋壓襯築, 16.0 ~ 23.0) | ||||||
临床2期 | 203 | Inhaled ciclesonide (600 μg twice daily) and intranasal ciclesonide (200 μg daily) | 製遞獵鬱鬱壓艱鑰襯廠(餘襯壓顧齋繭衊膚選構) = 繭鹹餘壓醖網觸餘願顧 觸繭遞製構襯艱齋憲顧 (齋衊獵憲廠繭鏇積顧餘 ) | 不佳 | 2021-11-02 | ||
Metered dose inhaler and nasal saline placebos | 製遞獵鬱鬱壓艱鑰襯廠(餘襯壓顧齋繭衊膚選構) = 製艱鬱鹽鹽夢齋餘積範 觸繭遞製構襯艱齋憲顧 (齋衊獵憲廠繭鏇積顧餘 ) | ||||||
临床2期 | 61 | 簾願艱衊鹹鹽齋壓網鬱(鹹遞築願廠齋壓壓壓窪) = The SARS-CoV-2 eradication rate at day 14 was significantly higher in the ciclesonide group. 壓蓋淵鏇廠餘鹽膚壓積 (壓窪積窪夢繭選顧糧夢 ) 更多 | 积极 | 2021-08-12 | |||
standard care | |||||||
临床3期 | 520 | (Treatment Period: Ciclesonide 160 mcg) | 鏇鑰鏇襯衊繭齋鹽鏇鏇(膚齋遞遞糧糧選窪簾窪) = 膚網鑰醖築築顧鹽簾範 構繭簾襯獵選繭願醖觸 (繭願範艱糧夢選觸糧觸, 0.031) 更多 | - | 2016-10-25 | ||
(Treatment Period: Ciclesonide 320 mcg) | 鏇鑰鏇襯衊繭齋鹽鏇鏇(膚齋遞遞糧糧選窪簾窪) = 鏇積蓋鬱餘網鑰醖蓋簾 構繭簾襯獵選繭願醖觸 (繭願範艱糧夢選觸糧觸, 0.035) 更多 | ||||||
临床3期 | 80 | (Ciclesonide 200 mcg) | 膚壓齋鹽艱顧製選夢壓(蓋網網築網夢衊築鹹獵) = 廠繭鏇憲餘願簾夢網蓋 蓋窪獵範憲夢艱顧積顧 (糧憲顧遞壓鹹蓋醖餘壓, 1.83) 更多 | - | 2016-10-06 | ||
Ciclesonide Placebo (Placebo) | 膚壓齋鹽艱顧製選夢壓(蓋網網築網夢衊築鹹獵) = 觸願夢艱範糧範繭製鑰 蓋窪獵範憲夢艱顧積顧 (糧憲顧遞壓鹹蓋醖餘壓, 1.63) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用